RAC 2.92% $1.94 race oncology ltd

RAC - Charts & Price Action, page-20316

  1. 90 Posts.
    lightbulb Created with Sketch. 83
    Agreed. What's not to like about the next 6+ months. New, easy to administer, high value formulation with the same properties that have previously shown CPACS will be in patients and clinically validated, opening up blockbuster commerical opportunities in the not too distant future. FOMO will be a factor, as there's not much time to be on the sidelines anymore.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.